Skip to main content
Premium Trial:

Request an Annual Quote

Fewer, But Better

The quality of scientific research and papers is suffering as an increased emphasis is being placed on the number of paper produced and how often they are cited, writes Arizona State University's Daniel Sarewitz in an essay at Nature.

He adds that this growth in papers and corresponding decline in quality was foreseen by Derek de Solla Price in the 1960s. Price had noted that the number of researchers and papers they produced had been growing exponential and that that wasn't sustainable, Sarewitz says. He notes Price was an "elitist who believed that quality could not be maintained amid such growth."

Today, Sarewitz says that a good portion of scientific reports isn't reliable. He notes that in cancer, a breast-cancer cell line that's been used a thousand times has been revealed to actually be a melanoma cell line. And, as an average paper is cited some 10 to 20 times in five years, findings based on contaminated samples are being amplified.

"It seems extraordinarily unlikely that these problems [of quantity and quality] will be resolved through the home remedies of better statistics and lab practice, as important as they may be. Rather, they would seem — and this is what Price believed — to announce that the enterprise of science is evolving towards something different and as yet only dimly seen," he adds.

Instead, the only cure Sarewitz sees is to publish fewer papers. "Rising quality can thus emerge from declining scientific efficiency and productivity," he says. 

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.